Whole brain radiotherapy with radiosensitizer for brain metastases

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Viani, Gustavo Arruda ^a   Manta, Gustavo Borges ^a   Fonseca, Ellen Carrara ^a   De Fendi, Ligia Issa ^a   Afonso, Sergio Luis ^a   Stefano, Eduardo Jose ^a  

^a Marilia Medical School   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; EFAPROXIRAL; GADOLINIUM TEXAPHYRIN; LONIDAMINE; METRONIDAZOLE; MISONIDAZOLE; RADIOSENSITIZING AGENT; THALIDOMIDE;

ANOREXIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; BRAIN RADIATION; BRAIN TUMOR; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COGNITION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; HYPOXEMIA; INFECTION; LEUKOPENIA; LUNG CARCINOMA; MALAISE; META ANALYSIS; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SCROTAL PAIN; SIDE EFFECT; SKIN DISCOLORATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; URINE COLOR; ADJUVANT THERAPY; ADULT; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SKULL IRRADIATION; TREATMENT OUTCOME;

ADULT; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE PROGRESSION; DOSE FRACTIONATION; HUMANS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 61649106061     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-1     Document Type: Article

References (43)

1. Neurologic complications of cancer. JB Posner, Philadelphia: F.A. Davis 1995
2. Radiation therapy for brain metastases. G Cairncross JH Kim J Posner, Ann Neurol 1979 7 529 541 10.1002/ana.410070606
3. Whole brain radiation therapy with or without stereotactic radiosurgery alone or in combination with temozolamide for brain metastases. A phase III study (abstract). DW Andrews CB Scott PW Sperduto, International Journal of Radiation Oncology, Biology, Physics 2002 54 93 98
4. Interim report of the JROSG99-1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1-4 brain metastases. H Aoyama H Shirato M Nakagawa, American Society of Clinical Oncology (40th Annual Meeting Proceedings) 2004 23 108
5. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. B Borgelt R Gelber S Kramer LW Brady CH Chang LW Davis, International Journal of Radiation Oncology, Biology, Physics 1980 6 1 9 6154024
6. Supportive Care Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. MN Tsao NS Lloyd RK Wong E Rakovitch E Chow N Laperriere, Cancer Treat Rev 2005 31 4 256 73 10.1016/j.ctrv.2005.04.007 15951117
7. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. D Kondziolka A Patel LD Lunsford A Kassam JC Flickinger, International Journal of Radiation Oncology, Biology, Physics 1999 45 427 34 10487566
8. A randomized trial of surgery in the treatment of single metastases to the brain. RA Patchell PA Tibbs JW Walsh, N Engl J Med 1990 322 494 500 2405271
9. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. RA Patchell PA Tibbs WF Regine, JAMA 1998 280 1485 1489 10.1001/jama.280.17.1485 9809728
10. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. L Gaspar C Scott M Rotman, Int J Radiat Oncol Biol Phys 1997 37 745 751 9128946
11. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. D Antonadou M Paraskevaidis G Sarris, J Clin Oncol 2002 20 3644 3650 10.1200/JCO.2002.04.140 12202665
12. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. D Khuntia M Mehta, Expert RevAnticancerTher 2004 4 981 9 10.1586/14737140.4.6.981
13. Thalidomide is an inhibitor of angiogenesis. RJ D'Amato MS Loughnan E Flynn, Proc Nat Acad Sci USA 1994 91 4082 4085 7513432 10.1073/pnas.91.9.4082
14. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. CG Lee M Heijn E di Tomaso, Cancer Res 2000 60 5565 5570 11034104
15. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. BA Teicher SA Holden G Ara, Int J Cancer 1994 57 920 925 10.1002/ijc.2910570624 7515861
16. RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases database. E Shaw C Scott J Suh, J Clin Oncol 2003 21 2364 2371 10.1200/JCO.2003.08.116 12805339
17. The Oxygen Effect and Reoxygenation. EJ Hall, Radiobiology for the Radiologist Philadelphia, PA, Lippincott 3 1988 137 160
18. Assessing the quality of reports of randomized clinical trials: is blinding necessary? AR Jadad RA Moore D Carroll, Control Clin Trials 1996 17 1 12 10.1016/0197-2456(95)00134-4 8721797
19. The combined use of radiation therapy and lonidamide in the treatment of brain metastases. LM DeAngelis VE Currie J-H Kim G Krol MA O'Hehir FM Farag, Journal of Neuro-oncology 1989 7 241 7 10.1007/BF00172917 2677257
20. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment of metastatic cancer to brain. HJ Eyre JD Ohlsen J Frank AF LoBuglio JD McCracken TJ Weatherall CM Mansfield, Journal of Neuro-oncology 1984 2 325 30 10.1007/BF00178115 6397578
21. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG- 7916). LT Komarnicky TL Phillips K Martz S Asbell S Isaacson R Urtasun, International Journal of Radiation Oncology, Biology, Physics 1991 20 53 8 1993631
22. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. TL Phillips CB Scott SA Leibel M Rotman IJ Weigensberg, International Journal of Radiation Oncology, Biology, Physics 1995 33 339 48 7673021
23. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. MP Mehta P Rodrigus CHJ Terhaard A Rao J Suh W Roa, Journal of Clinical Oncology 2003 21 2529 36 10.1200/JCO.2003.12.122 12829672
24. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial (abstract). MP Mehta R Gervais Chabot, J Clin Oncol 2006 24 367s 10.1200/JCO.2006.06.9096
25. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. JH Suh B Stea Nabid, J Clin Oncol 2006 24 106 114 10.1200/JCO.2004.00.1768 16314619
26. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). JP Knisely B Berkey A Chakravarti, Int J Radiat Oncol Biol Phys 2008 71 79 86 18164847
27. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. C Scott J Suh B Stea A Nabid J Hackman, Am J Clin Oncol 2007 6 580 7 10.1097/COC.0b013e3180653c0d
28. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. BD Kavanagh SR Khandelwal RK Schmidt- Ullrich, Int J Radiat Oncol Biol Phys 2001 49 1133 1139 10.1016/S0360-3016(00)01532-7 11240256
29. RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. MP Kunert JF Liard DJ Abraham, Am J Physiol 1996 271 H602 613 8770102
30. Efaproxiral: A novel radiation sensitiser. JH Suh, Expert Opin Investig Drugs 2004 13 543 550 10.1517/13543784.13.5.543 15155129
31. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. P Carde R Timmerman MP Mehta, J Clin Oncol 2001 19 2074 2083 11283141
32. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. M Presta P Dell' Era S Mitola, Cytokine Growth Factor Rev 2005 16 159 178 10.1016/j.cytogfr.2005.01.004 15863032
33. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. A Aigner M Butscheid P Kunkel, Int J Cancer 2001 92 510 517 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H 11304685
34. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. R Ansiaux C Baudelet BF Jordan, Clin Cancer Res 2005 11 2 pt 1 743 750 15701864
35. A RTOG (Radiation Therapy Oncology Group) Phase II study of conventional radiation therapy plus thalidomide followed by thalidomide post XRT for supratentorial glioblastoma. WKA Yung W Seiferheld B Donahue, Proc Am Soc Clin Oncol 2001 20 (abstract 206).
36. Targeting hypoxia cell signaling for cancer therapy. G Melillo, Cancer Metastasis Rev 2007 26 341 52 10.1007/s10555-007-9059-x 17415529
37. Exploiting tumour hypoxia in cancer treatment. JM Brown WR Wilson, Nat Rev Cancer 2004 4 437 47 10.1038/nrc1367 15170446
38. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. J Overgaard MR Horsman, Semin Radiat Oncol 1996 6 10 21 10.1016/S1053-4296(96)80032-4 10717158
39. ARCON: a novel biology-based approach in radiotherapy. JH Kaanders J Bussink AJ van der Kogel, Lancet Oncol 2002 3 728 37 10.1016/S1470-2045(02) 00929-4 12473514
40. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. IJ Hoogsteen LA Pop HA Marres, Int J Radiat Oncol Biol Phys 2006 64 83 9 16213107
41. Neurocognitive dysfunction in cancer patients. CA Meyers, Oncology (Huntington) 2000 14 75 79 discussion 79
42. Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. S Zimm GL Wampler D Stablein, Cǎncer 1981 48 384 394 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8
43. The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. JM Kurtz R Gelber LW Brady, Int J Radiat Oncol Biol Phys 1981 7 891 895 6171553